Claims
- 1. A killed immunogenic mammalian cancer cell having a cell surface marker incorporating a modified sialic acid unit capable of initiating an immune response in a mammalian system containing them which immune response is sufficiently strong to effectively combat proliferation of a live cancer cell.
- 2. The killed immunogenic mammalian cancer cell according to claim 1 wherein the modified sialic acid unit comprises an N-propionyl group.
- 3. The killed immunogenic mammalian cancer cell according to claim 2 wherein the N-propionyl group is derived from N-propionyl mannosamine.
- 4. The killed immunogenic mammalian cancer cell of claims 1, wherein said cell is autologous to said mammalian system.
- 5. The killed immunogenic mammalian cancer cell of claim 1, wherein said cell is allogeneic to said mammalian system.
- 6. An anti-cancer treatment comprising a pharmaceutically effective amount of a killed immunogenic mammalian cancer cell having a cell surface marker incorporating a modified sialic acid unit capable of initiating an immune response in a mammalian system containing them which immune response is sufficiently strong to effectively combat proliferation of a live cancer cell, in combination with a pharmaceutically acceptable carrier.
- 7. The anti-cancer treatment according to claim 6 wherein the modified sialic acid unit comprises an N-propionyl group.
- 8. The anti-cancer treatment according to claim 7 wherein the N-propionyl group is derived from N-propionyl mannosamine.
- 9. An anti-cancer treatment comprising co-administration of a cell according to claim 1 with N-propionyl mannosamine.
- 10. An anti-cancer treatment comprising co-administration of a cell according to claim 1 with an anti-cancer drug selected from the group consisting of cyclophosphamide, melphalan, adriamycin, decarbazine, armustine, cisplatin, tamoxifen, bleomycine, vincristine and lomustine.
- 11. The anti-cancer treatment according to claim 10 wherein the anti-cancer drug comprises cyclophosphamide.
- 12. Use of a killed immunogenic mammalian cancer cell according to claim 1 for preparation of an anti-cancer medicament.
- 13. An anti-cancer treatment comprising a pharmaceutically effective amount of a killed immunogenic mammalian cancer cell having a modified sialic acid unit on the surface thereof, said modified sialic acid unit comprising a N-propionyl polysialic acid, said cell being formed by, prior to killing the cell, incubating the cell with N-propionyl mannosamine, and subsequently killing the cell and combining the cell with a pharmaceutically acceptable carrier.
- 14. The anti-cancer treatment according to claim 13, wherein the cell is killed by heat treatment.
Parent Case Info
[0001] This application claims the benefit of priority under 35 USC 119 (e) of U.S. Provisional Patent Application No. 60/313,466 filed Aug. 21, 2001.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60313466 |
Aug 2001 |
US |